APA (7th ed.) Citation

Petrakis, I., Kontogiorgis, C., Nena, E., Delimpasi, S., Loutsidi, N. E., Spanoudakis, E., . . . Terpos, E. (2023). Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study. Cancers, 15(24), 5846. https://doi.org/10.3390/cancers15245846

Chicago Style (17th ed.) Citation

Petrakis, Ioannis, et al. "Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study." Cancers 15, no. 24 (2023): 5846. https://doi.org/10.3390/cancers15245846.

MLA (9th ed.) Citation

Petrakis, Ioannis, et al. "Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study." Cancers, vol. 15, no. 24, 2023, p. 5846, https://doi.org/10.3390/cancers15245846.